ALL	acute lymphoblastic leukemia
allo-HSCT	allogeneic hematopoietic stem cell transplantation
AML	acute myeloid leukemia
ATO	arsenic trioxide
AZA	azacytidine
BM	bone marrow
CDR	commonly deleted region
CHIP	clonal hemopoiesis of indeterminate potential
CK	complex karyotypes
CLL	chronic lymphocytic leukemia
cn-LOH	copy-neutral loss of heterozygosity
CR	complete remission
DAC	decitabine
DBD	DNA-binding domain
DDR	DNA damage responses
DNE	dominant negative effect
DSB	double-strand breaks
GOF	gain of function
H3K27me3	trimethylation of lysine 27 of histone H3
HMAs	hypomethylating agents
HSC	hematopoietic stem cell
HSPC	hematopoietic stem and progenitor cell
IHC	immunohistochemistry
IPSS	International Prognostic Scoring System
IPSS-R	revised International Prognostic Scoring System
LFS	Li-Fraumeni syndrome
LOH	loss of heterozygosity
MDM2	Murine Double Minute-2
MDS	myelodysplastic syndromes
MK	Monosomal karyotype
MM	multiple myeloma
MQ	methylene quinuclidinone
NGS	next generation sequencing
ORR	overall response rate
OS	overall survival
PFS	progression-free survival
PRC2	Polycomb repressive complex 2
RFS	relapse-free survival
RPs	ribosomal proteins
SNP	single-nucleotide polymorphism
t-AML	therapy-related acute myeloid leukemia
t-MDS	therapy-related myelodysplastic syndromes
t-MNs	therapy-related myeloid neoplasms
TP53	tumor protein p53
TPII	topoisomerase II
VAF	variant allele frequency
WPSS	WHO-based Prognostic Scoring System
WT	wild-type